A Phase I/II Open-Label Study TPI 287 in Combination With Temozolomide in Patients With Metastatic Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs TPI 287 (Primary) ; Temozolomide
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 07 Jul 2016 Status changed from active, no longer recruiting to discontinued due to low response rate.
- 23 Dec 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 14 Aug 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017 as per ClinicalTrials.gov record.